NCT00620230View on ClinicalTrials.gov

Safety and Tolerability of Single and Multiple Doses of VAK694 in Healthy and Atopic Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

46

Participants

Timeline

Start Date

October 31, 2007

Primary Completion Date

April 30, 2008

Study Completion Date

April 30, 2008

Conditions
Allergic Rhinitis
Interventions
DRUG

NVP-VAK694

DRUG

NVP-VAK694

Trial Locations (1)

33169

Novartis Investigator Site, North Miami Beach

Sponsors

Lead Sponsor

Novartis
All Listed Sponsors
lead

Novartis

INDUSTRY